DCZ0415

DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].

Product Specifications

CAS Number

[2242470-43-3]

UNSPSC

12352005

Target

Apoptosis; NF-κB

Type

Reference compound

Related Pathways

Apoptosis; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dcz0415.html

Purity

99.81

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=C1N(C2=CC=C(CC3=CC=NC=C3)C=C2)C(C4C5C(C6)C6C(C=C5)C14)=O

Molecular Formula

C23H20N2O2

Molecular Weight

356.42

References & Citations

[1]Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018.